TiGenix – American Depositary Shares (NASDAQ:TIG) was downgraded by equities research analysts at BTIG Research from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, January 16th. The analysts noted that the move was a valuation call.
TIG has been the topic of several other research reports. Zacks Investment Research upgraded shares of TiGenix – American Depositary Shares from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Thursday, January 11th. BidaskClub downgraded shares of TiGenix – American Depositary Shares from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Finally, Canaccord Genuity downgraded shares of TiGenix – American Depositary Shares from a “buy” rating to a “hold” rating and reduced their price target for the stock from $50.00 to $42.80 in a research report on Monday, January 8th.
Shares of TiGenix – American Depositary Shares (NASDAQ TIG) traded down $0.11 during trading on Tuesday, hitting $41.77. 571 shares of the stock were exchanged, compared to its average volume of 4,116. TiGenix – American Depositary Shares has a twelve month low of $14.30 and a twelve month high of $48.00. The company has a quick ratio of 1.36, a current ratio of 1.37 and a debt-to-equity ratio of 0.10.
ILLEGAL ACTIVITY NOTICE: “TiGenix – American Depositary Shares (NASDAQ:TIG) Downgraded by BTIG Research” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2018/02/11/btig-research-downgrades-tigenix-american-depositary-shares-tig-to-neutral.html.
About TiGenix – American Depositary Shares
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.